<SEC-DOCUMENT>0001513162-18-000058.txt : 20180308
<SEC-HEADER>0001513162-18-000058.hdr.sgml : 20180308
<ACCEPTANCE-DATETIME>20180308062528
ACCESSION NUMBER:		0001513162-18-000058
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171201
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20180308
DATE AS OF CHANGE:		20180308

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMERICA INC
		CENTRAL INDEX KEY:			0000073290
		STANDARD INDUSTRIAL CLASSIFICATION:	DENTAL EQUIPMENT & SUPPLIES [3843]
		IRS NUMBER:				952645573
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0531

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37863
		FILM NUMBER:		18674954

	BUSINESS ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614
		BUSINESS PHONE:		9496452111

	MAIL ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NMS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19871130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR MEDICAL SYSTEMS INC
		DATE OF NAME CHANGE:	19830216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR INSTRUMENTS INC
		DATE OF NAME CHANGE:	19720508
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8K.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<head><title>Form 8-K</title> </head> <body style="FONT-SIZE:10pt; FONT-FAMILY:'Times New Roman'; MARGIN-TOP:0px; COLOR:#000000"> <p style=MARGIN:0px><br></p> <p style="FONT-SIZE:14pt; MARGIN:0px" align=center><b>UNITED STATES</b></p> <p style="FONT-SIZE:14pt; MARGIN:0px" align=center><b>SECURITIES AND EXCHANGE COMMISSION</b></p> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center><b>WASHINGTON, DC 20549</b></p> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center>_______________</p> <p style="FONT-SIZE:16pt; MARGIN-BOTTOM:0px; MARGIN-TOP:21px" align=center><b>FORM 8-K</b></p> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:0px; MARGIN-TOP:16px" align=center><b>CURRENT REPORT</b></p> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center><b>Pursuant to Section 13 or 15(d) of the</b></p> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center><b>Securities Exchange Act of 1934</b></p> <p style="FONT-SIZE:11pt; MARGIN-BOTTOM:0px; MARGIN-TOP:7px" align=center>Date of Report (Date of earliest event reported):<b> &nbsp;December 1, 2017</b></p> <p style="FONT-SIZE:20pt; MARGIN-BOTTOM:0px; MARGIN-TOP:26px" align=center><b>BIOMERICA, INC.</b></p> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:16px; MARGIN-TOP:0px" align=center>(Exact name of registrant as specified in its charter)</p> <table style="FONT-SIZE:10pt; MARGIN-TOP:0px" cellpadding=0 cellspacing=0 align=center> <tr style=FONT-SIZE:0px> <td width=232> <td width=232> <td width=232 /> </tr><tr> <td width=232 height=17 style="MARGIN-TOP:0px; BORDER-BOTTOM:#000000 1px solid; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px"> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:2px; MARGIN-TOP:2px" align=center><b>Delaware</b></p></td> <td width=232 height=17 style="MARGIN-TOP:0px; BORDER-BOTTOM:#000000 1px solid; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px"> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:2px; MARGIN-TOP:2px" align=center><b>0-8765</b></p></td> <td width=232 height=17 style="MARGIN-TOP:0px; BORDER-BOTTOM:#000000 1px solid; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px"> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:2px; MARGIN-TOP:2px" align=center><b>95-2645573</b></p></td></tr> <tr> <td width=232 height=34 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:2px; MARGIN-TOP:2px" align=center>(State or Other Jurisdiction</p> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:2px; MARGIN-TOP:2px" align=center>of Incorporation)</p></td> <td width=232 height=34 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:2px; MARGIN-TOP:2px" align=center>(Commission</p> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:2px; MARGIN-TOP:2px" align=center>File Number)</p></td> <td width=232 height=34 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:2px; MARGIN-TOP:2px" align=center>(IRS Employer</p> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:2px; MARGIN-TOP:2px" align=center>Identification No.)</p></td></tr></table> <p style="MARGIN-BOTTOM:18px; MARGIN-TOP:8px"><br></p> <table style="FONT-SIZE:10pt; MARGIN-TOP:0px" cellpadding=0 cellspacing=0 align=center> <tr style=FONT-SIZE:0px> <td width=89> <td width=517> <td width=89 /> </tr><tr> <td width=89 height=17 style="MARGIN-TOP:0px; BORDER-BOTTOM:#000000 1px solid; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style=MARGIN:2px><br></p></td> <td width=517 height=17 style="MARGIN-TOP:0px; BORDER-BOTTOM:#000000 1px solid; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:2px; MARGIN-TOP:2px" align=center><b>17571 Von Karman Ave. Irvine, California</b></p></td> <td width=89 height=17 style="MARGIN-TOP:0px; BORDER-BOTTOM:#000000 1px solid; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:2px; MARGIN-TOP:2px" align=center><b>92614</b></p></td></tr> <tr> <td width=89 height=18 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style=MARGIN:2px><br></p></td> <td width=517 height=18 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px"> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:2px; MARGIN-TOP:2px" align=center>(Address of Principal Executive Offices)</p></td> <td width=89 height=18 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px"> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:2px; MARGIN-TOP:2px" align=center>(Zip Code)</p></td></tr></table> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:0px; MARGIN-TOP:16px" align=center>Registrant's telephone number, including area code: &nbsp;<b>(949) 645-2111</b></p> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:0px; MARGIN-TOP:16px" align=center><b>Not Applicable</b></p> <p style="FONT-SIZE:12pt; MARGIN:0px" align=center>(Former name or former address if changed since last report)</p> <p style="FONT-SIZE:12pt; MARGIN:0px">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="FONT-SIZE:1pt; MARGIN-BOTTOM:-1pt; MARGIN-TOP:16px" /> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:-2px; WIDTH:48px; MARGIN-TOP:0px; FLOAT:left">&#168;</p> <p style="FONT-SIZE:12pt; MARGIN:0px; TEXT-INDENT:-2px">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:-2px; WIDTH:48px; MARGIN-TOP:0px; FLOAT:left; CLEAR:left">&#168;</p> <p style="FONT-SIZE:12pt; MARGIN:0px; TEXT-INDENT:-2px">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:-2px; WIDTH:48px; MARGIN-TOP:0px; FLOAT:left; CLEAR:left">&#168;</p> <p style="FONT-SIZE:12pt; MARGIN:0px; TEXT-INDENT:-2px">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:-2px; WIDTH:48px; MARGIN-TOP:0px; FLOAT:left; CLEAR:left">&#168;</p> <p style="FONT-SIZE:12pt; MARGIN:0px; TEXT-INDENT:-2px">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p> <p style="CLEAR:left; MARGIN:0px"><br></p> <p style="FONT-SIZE:12pt; MARGIN:0px">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). &nbsp;&nbsp;Emerging growth company <font face=Wingdings>o</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<font style="FONT-FAMILY:'Wingdings'"><font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#61608;</font></font> </p> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:0px; MARGIN-TOP:16px">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <font face=Wingdings>o</font>&nbsp;&nbsp;<font style="FONT-FAMILY:'Wingdings'"><font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#61608;</font></font></p> <p style="MARGIN-BOTTOM:0px; MARGIN-TOP:16px"><br></p> <p style="MARGIN-BOTTOM:12px; MARGIN-TOP:0px" align=justify><br><br></p> <p style=MARGIN:0px align=center><br>&nbsp;</p> <p style="FONT-SIZE:9.5pt; MARGIN-BOTTOM:-2px; WIDTH:96px; MARGIN-TOP:0px; FLOAT:left"><b>Item 8.01 Other:</b></p> <p style="FONT-SIZE:9.5pt; MARGIN-BOTTOM:12px; MARGIN-TOP:0px; TEXT-INDENT:-2px" align=justify><b>Approval by Mexico<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s COFEPRIS and entry into distribution agreement</b></p> <p style="MARGIN-BOTTOM:16px; MARGIN-TOP:0px; CLEAR:left" align=justify><br></p> <p style="FONT-SIZE:9.5pt; MARGIN-BOTTOM:12px; MARGIN-TOP:0px" align=justify>The Company announced that it had received approval by Mexico<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s COFEPRIS for its colorectal screening test and had appointed DNA Biopharma (DNA) as its exclusive distributor for its EZ Detect product in Mexico. &nbsp;See the attached Press Release in the Exhibit Index.</p> <p style="MARGIN-BOTTOM:0px; MARGIN-TOP:15px" align=center><br><br></p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px><br></p> <p style="PAGE-BREAK-BEFORE:always; MARGIN:0px" align=center><br>&nbsp;</p> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:0px; MARGIN-TOP:15px" align=center><b>SIGNATURE</b></p> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:0px; MARGIN-TOP:10px; TEXT-INDENT:30px" align=justify>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p> <p style="MARGIN-BOTTOM:9px; MARGIN-TOP:0px"><br></p> <table style="FONT-SIZE:10pt; MARGIN-TOP:0px" cellpadding=0 cellspacing=0 align=center> <tr style=FONT-SIZE:0px> <td width=358> <td width=32> <td width=14> <td width=290 /> </tr><tr> <td width=358 height=20 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style=MARGIN:2px><br></p></td> <td width=32 height=20 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style=MARGIN:2px><br></p></td> <td width=14 height=20 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style=MARGIN:2px><br></p></td> <td width=290 height=20 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style=MARGIN:2px><br></p></td></tr> <tr> <td width=358 height=18 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style=MARGIN:2px><br></p></td> <td width=337 height=18 colspan=3 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:2px; MARGIN-TOP:2px"><b>BIOMERICA, INC.</b></p></td></tr> <tr> <td width=358 height=20 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style=MARGIN:2px><br></p></td> <td width=32 height=20 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style=MARGIN:2px><br></p></td> <td width=14 height=20 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style=MARGIN:2px><br></p></td> <td width=290 height=20 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style=MARGIN:2px><br></p></td></tr> <tr> <td width=358 height=20 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:2px; MARGIN-TOP:2px">Date: &nbsp;March 8, 2018</p></td> <td width=32 height=20 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:2px; MARGIN-TOP:2px">By:</p></td> <td width=14 height=20 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style=MARGIN:2px><br></p></td> <td width=290 height=20 style="MARGIN-TOP:0px; BORDER-BOTTOM:#000000 1px solid; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:2px; MARGIN-TOP:2px">/s/ Zackary S. Irani</p></td></tr> <tr> <td width=358 height=57 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style=MARGIN:2px><br></p></td> <td width=32 height=57 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style=MARGIN:2px><br></p></td> <td width=14 height=57 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style=MARGIN:2px><br></p></td> <td width=290 height=57 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:0px; PADDING-RIGHT:0px" valign=bottom> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:2px; MARGIN-TOP:2px">Zackary S. Irani<br>Chief Executive Officer</p></td></tr></table> <p style="MARGIN:0px; LINE-HEIGHT:2pt"><br></p> <p style="MARGIN-BOTTOM:9px; MARGIN-TOP:0px" align=center><br><br></p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px><br></p> <p style="PAGE-BREAK-BEFORE:always; MARGIN:0px" align=center><br>&nbsp;</p> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:9px; MARGIN-TOP:0px" align=center><b>EXHIBIT INDEX</b></p> <p style="FONT-SIZE:12pt; MARGIN:0px">Biomerica Press Release Dated March 8, 2018</p> <p style=MARGIN:0px><br><br></p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px><br></p></body>
<!-- EDGAR Validation Code: 49365986 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>Exhibit99.htm
<DESCRIPTION>EXHIBIT 99
<TEXT>
<HTML>
<head><title>EXHIBIT 99</title> </head> <body style="FONT-SIZE:10pt; FONT-FAMILY:'Times New Roman'; MARGIN-TOP:0px; COLOR:#000000"> <p style="FONT-SIZE:20pt; FONT-FAMILY:Univers (W1),Times New Roman; MARGIN:0px" align=center><img width=602 height=113 style="HEIGHT:48px; WIDTH:254px" src=graphic.jpg><strong><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<font style="FONT-SIZE:12pt; COLOR:#333333">NEWS</font><font style="FONT-SIZE:10pt; COLOR:#333333"> - For Immediate Release</font></em></strong></p> <p style=MARGIN:0px><br></p> <p style="FONT-SIZE:20pt; FONT-FAMILY:Univers (W1),Times New Roman; COLOR:#333333; MARGIN:0px" align=center><b><i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></b><font style=FONT-SIZE:19pt><b><i>&nbsp;</i></b></font><font style=FONT-SIZE:19pt><b><i>&nbsp;&nbsp;</i></b></font><font style=FONT-SIZE:19pt><b><i>&nbsp;</i></b></font><font style="FONT-SIZE:14pt; COLOR:#ff0000"><i>&nbsp;</i></font><font style=COLOR:#000000><b><i>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</i></b></font><br></p> <p style="FONT-SIZE:13pt; MARGIN-BOTTOM:8px; FONT-FAMILY:'Verdana'; MARGIN-TOP:0px; COLOR:#464646" align=center><b>Mexico<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s COFEPRIS (Mexico<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s equivalent of the FDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancer.</b></p> <p style="FONT-SIZE:13pt; MARGIN-BOTTOM:8px; FONT-FAMILY:'Verdana'; MARGIN-TOP:0px; COLOR:#464646; PADDING-LEFT:24px" align=center><b>-Biomerica ships first order to Mexico-</b></p> <p style="MARGIN:0px; LINE-HEIGHT:15pt" align=justify><br></p> <p style="FONT-SIZE:10.5pt; MARGIN-BOTTOM:5px; FONT-FAMILY:Avenir,Times New Roman; MARGIN-TOP:0px; COLOR:#002c40">Irvine, California <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#150;</font> March 8, 2018 -- Biomerica, Inc. (Nasdaq: BMRA) announced the Mexico<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s COFEPRIS (Comisi&#243;n Federal para la Protecci&#243;n contra Riesgos Sanitarios - Mexico<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s equivalent of the U.S. Food &amp; Drug Administration) approval of the EZ Detect<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#153;</font> colorectal screening test designed to help identify the early warning signs of colorectal cancer. &nbsp;&nbsp;</p> <p style="FONT-SIZE:10.5pt; MARGIN-BOTTOM:5px; FONT-FAMILY:Avenir,Times New Roman; MARGIN-TOP:5px; COLOR:#002c40">Biomerica also announced it has appointed DNA Biopharma (DNA) as its exclusive distributor for its EZ Detect product in Mexico and has shipped the first order of EZ Detect to the company. &nbsp;DNA has 25 years of expertise in marketing pharmaceutical and medical devices in Latin America. &nbsp;Oscar H. del Cid, CEO of DNA, stated, <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>We are excited about the prospects of colorectal cancer screening in Mexico. &nbsp;The EZ Detect product is unique in that it offers the opportunity of cost savings for the healthcare system while saving lives.<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font> &nbsp;</p> <p style="FONT-SIZE:10.5pt; MARGIN-BOTTOM:14px; FONT-FAMILY:Avenir,Times New Roman; MARGIN-TOP:0px; COLOR:#002c40; LINE-HEIGHT:15pt" align=justify>The EZ Detect colorectal screening test is the simplest at home test to detect fecal occult (hidden) blood, an early warning sign of colorectal cancer. The test does not require handling of stool or dietary restrictions.&nbsp; The EZ Detect pad is tossed into the toilet after a bowel movement.&nbsp; A change in the pad<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s color to blue/green, which would appear within two minutes, indicates the presence of blood in the stool.&nbsp; The pad is then simply flushed. &nbsp;</p> <p style="FONT-SIZE:10.5pt; MARGIN-BOTTOM:5px; FONT-FAMILY:Avenir,Times New Roman; MARGIN-TOP:5px; COLOR:#002c40">Zackary Irani, CEO of Biomerica, stated, <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>We are excited to work with Oscar and DNA to help enable colorectal screening in Mexico.<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font> </p> <p style="FONT-SIZE:10.5pt; MARGIN-BOTTOM:5px; FONT-FAMILY:Avenir,Times New Roman; MARGIN-TOP:5px; COLOR:#002c40"><b>About Biomerica (NASDAQ: </b><font style=COLOR:#0071bb><b>BMRA</b></font><b>)</b> </p> <p style="FONT-SIZE:10.5pt; MARGIN-BOTTOM:5px; FONT-FAMILY:Avenir,Times New Roman; MARGIN-TOP:5px; COLOR:#002c40">Biomerica, Inc. (<font style=COLOR:#0071bb>www.biomerica.com</font>) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on products for Gastrointestinal Disease, Diabetes and esoteric testing. </p> <p style="FONT-SIZE:10.5pt; MARGIN-BOTTOM:5px; FONT-FAMILY:Avenir,Times New Roman; MARGIN-TOP:5px; COLOR:#002c40">The Biomerica InFoods&#174; IBS product identifies patient specific foods that when removed may alleviate an individual's IBS symptoms. This patent-pending, diagnostic-guided therapy is designed to allow for a patient specific, guided dietary regimen to improve Irritable Bowel Syndrome (IBS) outcomes. The point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product will be the first for which the company will seek regulatory approval. A billable CPT code that can be used by both clinical labs and physicians' offices is available for InFoods&#174; diagnostic products. Since the InFoods&#174; product is a diagnostic-guided therapy, and not a drug, it has no drug type side effects.</p> <p style="FONT-SIZE:10.5pt; MARGIN-BOTTOM:5px; FONT-FAMILY:Avenir,Times New Roman; MARGIN-TOP:5px; COLOR:#002c40">The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other </p> <p style=MARGIN:5px><br><br></p> <hr size=1 noshade style="MARGIN-BOTTOM:9px; PADDING-TOP:9px"> <p style="FONT-SIZE:20pt; FONT-FAMILY:Univers (W1),Times New Roman; PAGE-BREAK-BEFORE:always; MARGIN:0px" align=center><img width=602 height=113 style="HEIGHT:48px; WIDTH:254px" src=graphic.jpg><strong><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<font style="FONT-SIZE:12pt; COLOR:#333333">NEWS</font><font style="FONT-SIZE:10pt; COLOR:#333333"> - For Immediate Release</font></em></strong></p> <p style=MARGIN:0px><br></p> <p style="FONT-SIZE:10.5pt; MARGIN-BOTTOM:5px; FONT-FAMILY:Avenir,Times New Roman; MARGIN-TOP:5px; COLOR:#002c40">written statements made or to be made by Biomerica) contains statements that are forward-looking; such as statements relating to intended launch dates, sales potential, significant benefits, market size, prospects, new products, favorable outlook, new distributors, expansion, increases in productivity and margins, expected orders, leading market positions, anticipated future sales or production volume of the Company, the launch or success of product and new product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.</p> <p style=MARGIN:0px>&nbsp;</p><font size=2><font size=2> <p align=left><font style=FONT-SIZE:10.5pt>Contact: Zackary Irani</font></p> <p><font style=FONT-SIZE:10.5pt>949-645-2111</font></p> <p style=MARGIN:0px></font></font><br>&nbsp;</p> <p style=MARGIN:0px><br><br></p></body>
<!-- EDGAR Validation Code: 71F8D7D8 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>graphic.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graphic.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !Q EP# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@!I(%,,B>H_.HI85FCV,/^^6*_RK#N/ .AW4?E
MS6"R)_==V;^9I*Y4>3[3:^1T/F*O=1^-1-<1+RTB#\:XN^^"O@K4L&Y\/VLA
M7^(;E8?D:Q9?V7_A;-))(_@S37=SN9FC//ZU/O=D=<887[4Y+T2_^2/09O$V
MEP*7?4;547[S-*HQ6=+\1/#4$>]_$&G(B_>=KJ/_ !KCO^&6?A5_T).F?]^C
M_C567]DGX3R-N/@ZT#?[#R+_ ":CW_(ZHPRS[4Y_<O\ Y([%OB]X*C&6\5:1
M_P"!L7_Q59A_:$^&O_0]>'?_  :0?_%USI_9#^$O_0GVO_?V7_XNH;C]COX2
M74+(_@^!5;KLGE5OS5ZI?(Z(QRC[4ZG_ ("O_DCH)?VCOAE"VQO'.AY]%OHS
M_(TW_AI3X9?]#KHW_@8G^-<M_P ,1_!P_P#,J2#_ +B5U_\ ':KS?L/_  @=
MMR>';F+V74;G^KFGJ=D(</OXIU?NC_F=3/\ M0?"V%MK>-M)S_LW"M_*H_\
MAJCX5?\ 0ZZ9_P!_/_K5Q5Q^P;\*YI-\6G7T'LE_+C]2:RKK_@GQ\.;B.1$N
MM9M]_P#%'=*2O_?2&LOWAVPH\,_;JU5\HGI?_#5'PJ_Z'/3?^_O_ -:D_P"&
MJ/A5_P!#IIO_ ']_^M7CUQ_P3E\%2-F'Q)KT7/\ $\!^;\(Q63=?\$V](D_X
M]O&=]'_UTME?_P!F%%IG=#!\)SWQ51>L?\D>\_\ #4GPK_Z';3/^_P *L?\
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M/<MI.I:5J\8_YZR202G\U8?^/5^BORKU91]32F9.[C\Z?*GT/I,-Q[GF$?\
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M+J?V=+?3%U"_O+Z0_NVE_>L&)_N[]OX5^7'PZ\+OXW\>>'- 7[NI:C;VCO\
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M2AAE'5+_ (=GX;BL=B<74G7<G9OY>2-_P%J7B+Q=XX\.:(-=U4+J6HV]H?\
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MSSGK_P !7HOL*_/S]L[P5_PA?[07B#8FVUUC9J<!_P"NG^L_\BK+7!_\+O\
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M;:1::5X;C<<7$,;7%Q'^+_+_ ..5\]#AO,9RLX)>K/I9\39="/NR;]$SZ/\
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MT5O^8EJ$>TNO_3-/O/\ C\M??GP5_9Q\*?!/3Q_9EO\ ;-5D3;<:I=?/-)[
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M_ RY_P#CE>V44OKV+_Y^R^]A_9^$_P"?<?N1Y=X6_9O^'G@N'5%T/PU%I_\
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M]SI>H6/S[]MOJ$N/I\Y:OHSK0?;BNZECL51^"I)?,\^IE^$JZSIQ?R1\T_\
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MN^;%A\&Y88S_ ,MM1UZVB_\ '%#&HI-1_: U5E-OI7@W1(_XOM5S<W3_ (;
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -
M6G444V)!3***0Q])114@+1113 93Z**8"-TIM%%,!12BBBI 6BBBF 4444 %
>%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
